Head: Thomas Oellerich, MD
The primary focus of our research is the biology and treatment of aggressive lymphomas and acute myeloid leukemia.
A mainstay of our laboratory is mass-spectrometry-based proteomics, which provides together with genomic approaches a foundation to understand the molecular pathophysiology of these cancers including their response to therapy. In addition to our efforts of characterizing patient-derived tumor samples by proteomic and genomic approaches, we have a strong interest in gaining detailed insights into i) the molecular mechanisms that induce malignant transformation, as well as ii) the resulting vulnerabilities in cancer cells that can be exploited therapeutically. For this purpose, we perform mechanistic research in disease models using molecular biology, biochemistry, and cell biology approaches. Moreover, we pursue a functional proteogenomic strategy where we use quantitative proteomic techniques to elucidate oncogenic signaling networks in combination with CRISPR/Cas9 loss-of-function screens which allow us to systematically identify regulators of cell survival and proliferation.
Our translational research efforts focus on 1.) the characterization of oncogenic signaling networks, 2.) the discovery of novel therapeutic targets, with a particular focus on non-oncogene addiction, 3.) the elucidation of the molecular mechanisms underlying therapy response and resistance and 4.) the identification of predictive biomarkers for targeted therapies. Our ultimate goal is to test the most promising candidates revealed by our research in clinical trials with the hope to improve our patient's outcome and their quality of life in the future.